Electric field-induced release and measurement (EFIRM) is a novel platform allowing detection of ctDNA containing EGFR mutations directly from both plasma and saliva in early- and late-stage NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.